ArticleJournal of inflammation research2025
Syndrome Differentiation and Treatment of Psoriasis by Traditional Chinese Medicines: An Integrating Study of Multi-Omics Analysis and Experimental Validation.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The molecular basis underlying the clinical differentiation in treating psoriasis with syndromes of blood-heat or blood-stasis in traditional Chinese medicine remains unclear. This study employs an integrated multi-omics approach to explore the similarities and differences in the pathogenic mechanisms of these two syndromes, and to elucidate the molecular foundations of Compound Qingdai Capsule and Yinxiekang Pian, which are representative formulas for syndrome-specific treatment, thereby providing insights into the scientific connotation of syndrome differentiation and treatment. Methods: Multi-omics data were integrated with machine learning to identify genes differentiating the two syndromes of psoriasis. The therapeutic mechanisms were explored through network pharmacology and molecular docking. Finally, in vivo experiments involved constructing composite psoriasis models in SD rats by combining traditional Chinese medicine syndromes with imiquimod induction, and analyzing skin lesion tissues via qPCR and ELISA. Results: After constructing the psoriasis pathway network and successfully establishing rat models, the research identified the characteristic genes of blood-heat syndrome psoriasis as Conclusion: GSK3B and AKT1 are differentially expressed in blood-heat syndrome and blood-stasis syndrome psoriasis respectively, while STAT1 is a common inflammatory mediator for both. Compound Qingdai Capsule and Yinxiekang Pian respectively provide a theoretical basis for traditional Chinese medicine syndrome differentiation and treatment of psoriasis by intervening in the same or different inflammatory targets and signaling pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.